May 11, 2016 · In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly ...
People also ask
What were the results of the Tryphaena trial?
What were the results of the aphinity study?
What is the difference between trastuzumab and pertuzumab?
What is the drug for neoadjuvant pertuzumab trastuzumab?
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): ...
5-year analysis of neoadjuvant pertuzumab and ... - The Lancet
www.thelancet.com › article › fulltext
May 11, 2016 · NeoSphere was a randomised, multicentre, international, open-label, phase 2 study. Patients were recruited from 59 centres in 16 countries.
Missing: centre- | Show results with:centre-
Feb 9, 2017 · NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared ...
NeoSphere is a central player management system that enables our business modules to work seamlessly across all channels to support the management of your ...
Missing: centre- | Show results with:centre-
Dec 6, 2011 · ... (NeoSphere): a randomised multicentre, open-label, phase 2 trial ... Affiliation. 1 Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy.
The addition of pertuzumab to trastuzumab–docetaxel neoadjuvant treatment for 12 weeks in the randomized, multicenter, open-label NeoSphere trial resulted in a ...
May 20, 2021 · Findings The follow-up results of this randomized multicenter phase 3 trial of 438 patients with stage II and III ERBB2-positive breast cancer ...
May 20, 2015 · Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab ...
Neo Sphere, organisme de formation professionnelle en presentiel, diplômes RNCP et certifications en e-learning à distance, éligibles CPF.